Close Menu

Eli Lilly

NEW YORK (GenomeWeb) — Biomarker development firm Denovo Biopharma has acquired the late-stage oncology drug enzastaurin from Eli Lilly and Company, and plans to use its genotyping platform to uncover a genomic marker or markers that can support new clinical trials advancing the drug for a genomi

NEW YORK (GenomeWeb) — As part of its quest to become a catch-all provider of tools and technologies for molecular diagnostic and especially companion diagnostic development, Qiagen has added another molecular analysis platform to its portfolio.

Originally published June 3.
NEW YORK (GenomeWeb) – Data from two large studies that tested the efficacy of widely used targeted drugs in molecularly defined breast cancer and colorectal cancer populations failed to show superiority of one therapeutic strategy over another.

This article has been updated from a previous version as Qiagen clarified an earlier statement regarding its acquisition of PrimeraDx.

NEW YORK (GenomeWeb News) – The New York Economic Development Corporation said today it has launched an initiative that will inject $100 million into life sciences startup companies located in the city through a mix of money from city government, life sciences companies, and venture capital partn

NEW YORK (GenomeWeb News) – Qiagen and Lilly inked their third companion diagnostic deal this week.
The companies did not disclose the drug or the molecular diagnostic target that the test will gauge.

Neurology biomarker firm C2N Diagnostics is accelerating its test development efforts with the aim of commercializing protein markers for the early detection of Alzheimer's as well as for use as primary endpoints in Phase III clinical trials of therapies for the disease.

NEW YORK (GenomeWeb News) — Exosome Diagnostics said today that it has entered into a collaboration agreement with Eli Lilly for biomarker discovery and validation using Exosome's EXO50 nucleic acid extraction kit.

Exosome Diagnostics this week announced that it has signed a deal to collaborate with Eli Lilly on mRNA and microRNA biomarker discovery and validation.

Combining metabolomics and proteomics, a consortium of academic and industry researchers has identified a signature that appears useful for predicting death in sepsis patients.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.